Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 24, No. 1-2, 2009
Issue release date: July 2009
Section title: Original Paper
Cell Physiol Biochem 2009;24:95–104
(DOI:10.1159/000227817)

Barbigerone, a Natural Isoflavone, Induces Apoptosis in Murine Lung-Cancer Cells via the Mitochondrial Apoptotic Pathway

Li Z.-G.1,* · Zhao Y.-L.1,* · Wu X.1,* · Ye H.-Y.1 · Peng A.1 · Cao Z.-X.1 · Mao Y.-Q.1 · Zheng Y.-Z.1 · Jiang P.-D.1 · Zhao X.2 · Chen L.-J.1 · Wei Y.-Q.1
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 1Department of Gynecology and Obstetrics, Second West China Hospital,2West China Medical School, Sichuan University, Chengdu 610041, China,*These authors contributed equally to this work
email Corresponding Author

Yu-Quan Wei and Li-Juan Chen

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital

West China Med School, Sichuan University, 1 Keyuan Road 4, Gaopeng Street

High Technological Development Zone, Chengdu 610041 (China)

Tel. +86-28-85164063, Fax +86-28-85164060, E-Mail yuquawei@vip.sina.com

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Barbigerone is a naturally occurring isoflavone with antioxidant activity. In present study, we investigated the antitumor activity of barbigerone against murine lung cancer cells LL/2 and the possible mechanism in vitro. Our results showed that barbigerone inhibited LL/2 cells proliferation in a concentration- and time-dependent manner and caused apoptotic death of LL/2 cells. Barbigerone-induced apoptosis was characterized by enhanced mitochondrial cytochrome c release, activation of caspase-3,-9, but not caspase-8. Exposure of LL/2 cells to barbigerone resulted in upregulation of Bcl-2-associated protein (Bax) and down-regulation of Bcl-2. In addition, proliferation inhibitory effect of barbigerone was associated with decreased level of phosphorylated p42/44 mitogen-activated protein kinase (p42/44 MAPK) and phosphorylated Akt. Moreover, barbigerone exhibit less toxicity to non-cancer cells than tumor cells. In conclusion, our results indicated that barbigerone can inhibit murine lung cancer cell proliferation by inducing apoptosis via mitochondrial apoptotic pathway and by decreasing phosphorylated p42/44 MAPK and Akt. Its potential to be a candidate of anti-cancer agent is worth being further investigated.

© 2009 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: April 24, 2009
Published online: July 01, 2009
Issue release date: July 2009

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: http://www.karger.com/CPB


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.